Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

S'inscrire

ALLO Allogene Therapeutics Inc

3,07

0,31 (11,23%)

14 Mai 2024 - Fermé

Retardé de 15 minutes

Ethereum Blockchain Game Pikamoon Raises $3.6m, Final ICO Phase Selling Out Fast

Dubai, United Arab Emirates, July 11th, 2023, Chainwire Pikamoon, an emerging Ethereum blockchain game, has raised $3.6 million in its ... Read more
https://www.valuewalk.com/ethereum-blockchain-game-pikamoon-raises-3-6m-final-ico-phase-selling-out-fast/

Allogene Therapeutics (NASDAQ:ALLO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024

Plus de graphiques de la Bourse Allogene Therapeutics

Allogene Therapeutics (NASDAQ:ALLO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024

Plus de graphiques de la Bourse Allogene Therapeutics

Actualités Allogene Therapeutics Inc

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
Lundi 13 Mai 2024 ( il y a 4 heures) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Lundi 13 Mai 2024 ( il y a 4 heures) • Edgar (US Regulatory)

Form 8-K - Current report
Lundi 13 Mai 2024 ( il y a 4 heures) • Edgar (US Regulatory)

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
Lundi 13 Mai 2024 ( il y a 4 heures) • GlobeNewswire Inc.

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Lundi 6 Mai 2024 ( il y a 1 semaine) • GlobeNewswire Inc.

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Vendredi 26 Avril 2024 ( il y a 2 semaines) • GlobeNewswire Inc.

Allogene Therapeutics Announces Q2 Investor Conference Participation
Mardi 9 Avril 2024 ( il y a 1 mois) • GlobeNewswire Inc.

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Jeudi 14 Mars 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Mardi 12 Mars 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Mardi 5 Mars 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
Mercredi 28 Février 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Form 8-K - Current report
Vendredi 16 Février 2024 ( il y a 3 mois) • Edgar (US Regulatory)

Plus d'articles sur Allogene Therapeutics Inc

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales